posted on Monday, 15th November 2021
Not tagged.
Permalink
During the prostate screening trial, called IMPACT, Paul's
fifth annual check revealed he had an elevated PSA (prostate
specific antigen) level in his blood.
Read the full article on BBC News:
Yearly
prostate checks benefit some men aged 40 plus
posted on Thursday, 18th February 2021
Not tagged.
Permalink
The CAPP2 clinical trial
led by Professor Sir John Burn, Newcastle University, has been
highlighted by the American Society of Clinical Oncology as an
Advance in Progress Against Cancer in their
16th Annual Report. The CAPP2 long term follow up paper was
published in the
Lancet in 2020.
It is a significant step for this cancer chemoprevention
research to be noted by the American Society of Clinical
Oncology.
CaPP3 is the follow up dose non-inferiority trial to
determine if this cancer chemoprevention can be observed with a
lower dose of aspirin.